

# Improving the Production of Riboflavin by Introducing a Mutant Ribulose 5-Phosphate 3-Epimerase Gene in *Bacillus Subtilis*

**Bin Yang**

Dalian Polytechnic University

**Yiwen Sun**

Dalian Polytechnic University

**Shouying Fu**

Tianjin University of Science and Technology

**Miaomiao Xia**

Tianjin Institute of Industrial Biotechnology Chinese Academy of Sciences

**Chuan Liu**

Tianjin Institute of Industrial Biotechnology Chinese Academy of Sciences

**Chunzhi Zhang** (✉ [Zhangcz@dlpu.edu.cn](mailto:Zhangcz@dlpu.edu.cn))

Dalian Polytechnic University

**Dawei Zhang**

Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences <https://orcid.org/0000-0001-5555-6151>

---

## Research Article

**Keywords:** Ribulose 5-phosphate, guanosine 5'-triphosphate, Embden-Meyerhof-Parnas pathway, overexpression

**Posted Date:** March 22nd, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-335981/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background:** Ribulose 5-phosphate (Ru5P) and guanosine 5'-triphosphate (GTP) are two key precursors of riboflavin, whereby Ru5P is also a precursor of GTP (purine *de novo* synthesis pathway). As a product of the oxidative pentose phosphate pathway (OPPP), Ru5P can flow back into the Embden-Meyerhof-Parnas pathway (EMP) through the non-oxidative pentose phosphate pathway (NOPPP). Major enzymes of the NOPPP include transaldolase (Tal), transketolase (Tkt), and ribulose 5-phosphate 3-epimerase (Rpe), which catalyze the conversion of Ru5P into xylulose 5-phosphate (X5P). Thus, inactivation of Rpe can reduce the consumption of Ru5P, enhancing the carbon flux toward riboflavin biosynthesis. However, there are no studies on the mutation or deletion of Rpe for improving riboflavin production.

**Results:** We mutated the genomic copy of *rpe*, in the riboflavin-producing *Bacillus subtilis* BSLY. The resulting strain BSR produced  $320.50 \pm 31.28$  mg/L of riboflavin in a fermentation medium containing 40 g/L sucrose as the carbon source, representing a 5-fold increase over the parental strain. We also constructed an *rpe* nonsense mutation strain BSRN, which produced  $365.69 \pm 27.53$  mg/L riboflavin in fermentation medium. However, BSRN had a growth defect compared with BSR and BSLY, which was also present in media containing glucose, maltose, and fructose. The growth of BSRN was restored when mutant or wild-type *rpe* was overexpressed. Notably, BSR exhibited respective increases of the inosine and guanine titers by 163% and 40%. Furthermore, a 35.96-fold increase of inosine 5'-monophosphate (IMP) titer was detected in BSRN. The transcription levels of most OPPP, purine, and GTP synthesis genes were unchanged in BSR, except for the levels of *zwf* and *ndk*, which were respectively 49% lower and 310% higher than in BSLY. The production of riboflavin was increased to  $479.90 \pm 33.21$  mg/L when *ribA* was expressed in BSR. The expression of *zwf*, *gntZ*, *prs*, and *purF*, respectively enhanced the riboflavin production by 48%, 31%, 26%, and 35%. Finally, overexpression of the *rib* operon by the pMX45 plasmid and mutant *gnd* by pHP03 plasmid in BSR led to a 3.05-fold increase of the riboflavin production ( $977.29 \pm 63.44$  mg/L).

**Conclusions:** This paper describes a mutation of the ribulose 5-phosphate 3-epimerase and its influence on riboflavin production. The results of qRT-PCR and HPLC analyses indicated that the *rpe* mutant showed a different pattern of purine metabolism, while the cells maintained generally normal levels of the transcription of genes related to PPP and purine *de novo* synthesis pathways. With the increased expression of genes in the OPPP, purine, and riboflavin synthesis pathways, the production of riboflavin was effectively enhanced, showing the potential for further engineering of this strain.

## Background

Riboflavin, also known as Vitamin B<sub>2</sub>, is an isoalloxazine derivative that was previously produced by chemical synthesis. But over the last decades, microbial fermentation has become dominant in its industrial production [1]. Animals must acquire this essential cofactor from food sources [2], while most of bacteria, fungi, and plants can synthesize it using native metabolic pathways. The most commonly used riboflavin producers are bacteria and fungi, such as *Bacillus subtilis* [3–7], *Ashbya gossypii* [8, 9],

and *Candida famata* [10]. As a traditional industrial strain, *A. gossypii* can produce 15 g/L riboflavin in fed-batch fermentation [11], while *Candida famata* can produce 20 g/L riboflavin after 200 h of fermentation [12]. *B. subtilis* is a superior host, which can reach a titer of 20–27 g/L, after a rapid fermentation process of 3 days [13].

The riboflavin biosynthesis pathway and its regulation in *B. subtilis* have been comprehensively studied [14–16]. The two precursors Ru5P and GTP are derived from the oxidative pentose phosphate pathway (OPPP) (Fig. 1 orange area) and purine *de novo* biosynthesis pathway (Fig. 1 brown area), respectively. Then, Ru5P and GTP enter the riboflavin synthesis pathway (Fig. 1 yellow area), which is composed of a series of enzymes encoded by the *rib* operon. As a branch of central carbon metabolism, the PPP generates pentoses from hexoses through oxidative reactions, and at the same time produces NADPH, which serves as the major source of reducing power for biosynthetic reactions (Fig. 1 orange and area) [17]. Ru5P is the direct product of the OPPP, and it is converted into ribose 5-phosphate (R5P) by ribose 5-phosphate isomerase. Then, R5P is converted into phosphoribosylpyrophosphate (PRPP) by phosphoribosylpyrophosphate synthetase. PRPP is a precursor for the *de novo* biosynthesis of L-histidine, L-tryptophan, NAD, NADP, pyrimidines, and purines, including GTP, the other precursor for riboflavin biosynthesis.

Many regulatory mechanisms of riboflavin biosynthesis have been studied. The 5'-untranslated region of the mRNA of the *rib* operon contains a riboswitch sequence, which can form a stem-loop structure when bound to flavin mononucleotide (FMN), causing premature transcription termination [18]. Similar to the *rib* operon, the purine operon also contains a riboswitch region that can bind purine compounds to form a secondary structure [19]. The transcriptional regulator PurR controls the expression of the purine operon at the transcriptional level [20]. Additionally, the purine *de novo* synthesis pathway is regulated through feedback inhibition of enzymes. For example, phosphoribosyl-pyrophosphate synthetase (Prs) is inhibited by ADP and GDP [21, 22], while glutamine phosphoribosylpyrophosphate amidotransferase (PurF) is inhibited by ATP, ADP, AMP, GTP, GDP, and GMP [23]. The enzymes in the PPP are also regulated by metabolic intermediates and products of the pathway. For example, glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6GPD) are inhibited by NADPH, ATP, and fructose 1,6-bisphosphate (FBP) [24].

Many metabolic engineering strategies were developed to modify the flux of the synthetic pathways and regulatory elements in riboflavin-producing strains. To enhance the biosynthesis of Ru5P, G6PD was overexpressed in *B. subtilis* PY, which led to a 25% increase of riboflavin production [25]. Feedback-resistant mutants of G6PD and 6GPD from *Corynebacterium glutamicum* were also characterized, and applied to improve the production of riboflavin in *B. subtilis* [26]. The transcriptional regulator gene *purR* and riboswitch sequence were deleted, which deregulated the purine *de novo* synthesis pathway to improve the supply of GTP [27].

As discussed above, Ru5P is a precursor for both riboflavin and GTP synthesis, and enhancing its synthesis or decreasing its consumption could have two-fold benefits for riboflavin production. Produced

by the OPPP (Fig. 1 orange area), Ru5P can enter the NOPPP (Fig. 1 blue area) to generate other sugar phosphates, such as erythrose 4-phosphate (E4P), which is a precursor for the biosynthesis of aromatic amino acids, vitamin B6, and vitamin K [28]. Ribulose 5-phosphate 3-epimerase (encoded by *rpe* in *B. subtilis*) catalyzes the first step of the NOPPP, converting Ru5P into xylulose 5-phosphate (X5P). In previous studies, *B. subtilis* strains possessing a mutant *rpe* or *tkt* gene were found to produce D-ribose [29, 30]. However, these articles did not specify the sequence of the relevant mutation. And the influence of the mutant *rpe* on riboflavin production has not been studied yet. In this study, the chromosomal *rpe* gene of a riboflavin-producing *B. subtilis* was mutated by homologous recombination. Then, the riboflavin production, physiology, and metabolic characteristics of the resulting engineered strain were studied. Additionally, other genes were overexpressed in this strain to further enhance riboflavin production. This work exemplifies a strategy for improving the riboflavin production in *B. subtilis* by mutating the *rpe* gene, and may serve as a reference for detecting potential bottlenecks in riboflavin biosynthesis in *rpe* mutant strains.

## Results

### Mutation of ribulose 5-phosphate 3-epimerase dramatically increases the production of riboflavin in *B. subtilis*

In the first step of NOPPP, ribulose 5-phosphate 3-epimerase converts Ru5P into X5P, so that the pentose phosphate can flow back into the Embden-Meyerhof-Parnas-pathway (EMP). The chemical structure of X5P allows transketolase to transfer a two-carbon glycoaldehyde unit to R5P, generating sedoheptulose 7-phosphate (S7P) and glyceraldehyde 3-phosphate (G3P). Furthermore, transketolase can generate fructose 6-phosphate (F6P) and erythrose 4-phosphate (E4P) from S7P and G3P. In *B. subtilis*, ribulose 5-phosphate 3-epimerase is encoded by *rpe*, which is part of a putative operon with nine genes (Fig. 2A, including *defA*, *fmt*, *yloM*, *yloN*, *prpC*, *prkC*, *cpgA*, *rpe*, and *yloS*). None of the other eight genes has a known function related to riboflavin biosynthesis. In 2014, the genome of an EU-unauthorized genetically modified riboflavin-producing *B. subtilis* strain was sequenced [31], and we found an *rpe* mutation in the genomic database of this strain. One of seven adenines from position 498 to 504 is missing in the nucleotide sequence of this mutant, which shifts the reading frame, resulting in a truncated Rpe protein (217 aa to 170 aa) (Fig. 2B).

To clarify the influence of the *rpe* mutation on riboflavin production, a riboflavin producer *B. subtilis* LY (BSLY), was constructed on the background of *B. subtilis* 168 according to previous references. BSly carries a deregulated *rib* operon on the chromosome [27], as well as a mutation in the adenylosuccinate synthetase (PurA (P242L)) [3] that reduces the carbon flow from IMP to AMP. After 48 h of fermentation with sucrose as the carbon source, BSly produced  $37.29 \pm 1.32$  mg/L of riboflavin. The mutant *rpe* gene was introduced into the wide-type chromosomal *rpe* locus of BSly to generate *B. subtilis* R (BSR), which produced remarkably more riboflavin ( $320.50 \pm 31.28$  mg/L) compared to BSly (Fig. 2C), although its growth rate was insignificantly reduced (data not shown). To clarify whether the increase of productivity was caused by decreased Rpe activity, we introduced a nonsense *rpe* mutation (the start codon ATG was

mutated into the stop codon TAA) at the same locus to generate BSRN. BSRN produced  $365.69 \pm 27.53$  mg/L of riboflavin, while the mutation significantly inhibited the growth of the strain (data not shown). It indicated that the truncation of Rpe may to a certain extent decrease the activity of this enzyme, and thereby lead to a decrease of the carbon flow back to the EMP via the NOPPP.

The deficiencies of Rpe and Tkt were previously reported to increase the production of D-ribose in *B. subtilis* [29, 32]. We therefore introduced a nonsense mutation of *tkt* (the start codon ATG was mutated into the stop codon TAA) in the BSLY and BSR to generate BST and BSRT, respectively. These mutations led to an improvement of riboflavin production in shake-flasks fermentation after 48 h. The riboflavin titer of BST reached  $194.09 \pm 27.76$  mg/L at 60 h, which was a 5-fold increase over the parental strain. Moreover, the riboflavin titer of BSRT reached  $678.53 \pm 8.81$  mg/L at 60 h, 2-fold higher than that of BSR. These results indicate that the inactivation of Tkt aggravated the deficiency of the cells to reuse pentose phosphates, and the blockage of the NOPPP remarkably increased the carbon flow toward riboflavin biosynthesis.

**Growth phenotype and enzyme activity of mutants deficient in Rpe**

The mutation of *rpe* led to a growth defect, which was shown in fermentation. To evaluate this deficiency more systematically and accurately, GMI media with four different carbon sources (glucose, sucrose, maltose, and fructose) were used in the growth experiments. Overnight cultures of BSLY, BSR, and BSRN in LB were washed with GMI medium contained the indicated carbon source and cultured on plates. The growth of BSR was insignificantly slower than that of BSLY, while BSRN showed a marked growth defect (Fig. 3 left). The expression of wild-type and truncated Rpe restored the growth of BSRN (Fig. 3 right) which indicated that Rpe catalyzes a reaction that provides a precursor needed for rapid biosynthesis of cellular components. We inferred that this metabolite is E4P, which is a precursor of aromatic amino acids, vitamin B<sub>6</sub>, and vitamin K. Although deficient in Rpe, E4P can also be generated by transketolase using glyceraldehyde 3-phosphate and fructose 6-phosphate as substrates. To confirm the metabolic defect in the *rpe* mutants, the cell extracts of BSLY, BSR, and BSRN were used to test their Rpe activities (Table 1). The conversion rate of Ru5P to X5P in BSLY was  $0.707 \pm 0.115$  μmol/min/μg protein compared to  $0.436 \pm 0.086$  μmol/min/μg protein in BSR. Moreover, there was no detectable Rpe activity in BSRN.

Table 1  
Rpe activities in BSLY, BSR, and BSRN

	Strain		
	BSLY	BSR	BSRN
Rpe activities (μmol/min/μg protein)	$0.707 \pm 0.115$	$0.436 \pm 0.086$	Not detectable

**Investigating the mechanism of increased riboflavin biosynthesis in the *rpe* mutant strain**

To investigate the mechanism of riboflavin overproduction in the *rpe* mutants, the purine compounds in the cell culture of BSR, BSRN and BSLY were compared. The cell suspension was extracted at 48 h of the fermentation and the concentrations of purines were measured as "Materials and Methods" described. As shown in Table.2, the concentrations of AMP and IMP were similar between BSR and BSLY. While the concentrations of GMP and XMP in BSR was 35% and 132% relative to BSLY. And BSR produced  $97.31 \pm 0.48$  µg/L inosine and  $71.73 \pm 0.65$  µg/L guanosine, which was respectively 163 and 40%, more than in BSLY. Notably, the titer of IMP of BSRN reached  $218.98 \pm 1.05$  µg/L, which was 6 times that of BSLY. These results indicated that the purine metabolism of these mutants was changed. The increased concentration of IMP may also contribute to the growth defect of BSRN.

Then, the transcription levels of the genes related to the PPP and purine synthesis pathway in BSR and BSLY were measured by qRT-PCR. As shown in Fig. 4B, the transcription levels of these genes were practically the same in BSR and BSLY, except for *zwf* and *ndk*, which respectively exhibited a 49% decrease and a 310% increase. These results indicated that the variation of metabolic flux toward purine compounds synthesis did not require a general activation of transcription of the pathway genes. The transcription of the purine operon is regulated by PurR, and its regulation is mediated by adenine [33]. There was also no difference of adenine concentration in these strains (Table 2). Increased expression of *ndk* indicated that there is an imbalance of the nucleotide pools, which was also shown in the results of HPLC analysis (Table 2). In addition, the transcription levels of ribose 5-phosphate isomerase (encoded by *ywlF*), and transketolase (encoded by *tkt*), which also catalyze reactions related to Ru5P, were slightly reduced in the *rpe* mutant (Fig. 4).

Table 2

Concentration of purine compounds in the cultures of *B. subtilis* strains developed in this study

Strain	Concentration (µg/L)						
	adenine	inosine	guanosine	GMP	AMP	IMP	XMP
BSLY	$11.73 \pm 0.48$	$37.07 \pm 0.50$	$50.89 \pm 0.82$	$5.00 \pm 0.15$	$3.07 \pm 0.10$	$6.09 \pm 0.16$	$1.65 \pm 0.18$
BSR	$11.46 \pm 0.41$	$97.31 \pm 0.48$	$71.73 \pm 0.65$	$1.76 \pm 0.19$	$3.05 \pm 0.24$	$6.26 \pm 0.19$	$2.17 \pm 0.14$
BSRN	$16.16 \pm 0.68$	$222.87 \pm 1.32$	$79.38 \pm 0.42$	$3.50 \pm 0.39$	$3.55 \pm 0.34$	$218.98 \pm 1.05$	$1.92 \pm 0.21$

### Improving the riboflavin production by overexpressing the genes related to the PPP, purine de novo synthesis pathway and riboflavin biosynthesis pathway

The sufficient supply of precursors and energy, as well as a proper ratio of the two precursors, is vital for riboflavin biosynthesis. To investigate the limiting reactions in riboflavin synthesis, genes of the PPP, purine *de novo* synthesis pathway, and riboflavin biosynthesis pathway were individually integrated into the mid-copy-number expression plasmid pMA5 (spe). These plasmids were introduced into BSR generating BSR02-BSR10. As shown in Fig. 5A, with the expression of *ribA*, the production of riboflavin

reached  $479.90 \pm 33.21$  mg/L at 48 h, representing a 2-fold increase compared with the strain carrying pMA5 (spe). The expression of *zwf*, *gntZ*, *purF*, and *prs* increased the production of riboflavin by 48%, 31%, 26%, and 35% respectively, while the expression of *ykgB*, *gmk*, and *guaA* had a negative effect.

These results indicated that the bifunctional enzyme RibA is still a major bottleneck of riboflavin biosynthesis in the *rpe* mutant, which was in agreement with previous studies [34]. Furthermore, the expression of G6PD and 6GPD is beneficial for the supply of precursors, since these enzymes catalyze key steps in the PPP. The expression of *purF* and *prs* increases the flux toward purine biosynthesis, while the expression of *guaA* and *gmk* may cause an accumulation of the intermediates (GMP and GDP) in this pathway, which inhibits the activities of the enzymes of downstream purine biosynthesis. Furthermore deletion of *Zwf* and *YqeC* severely impaired the synthesis of riboflavin in the *rpe* mutant (Fig. 5B), indicating that these two enzymes are key points that control the flux of OPPP.

To investigate the influence of the expression of the *rib* operon on riboflavin production in the *rpe* mutant, the low-copy-number pSM19035-derived plasmid pMX45 carrying a complete *rib* operon [3] was introduced into BSR to generate BSR01. BSR01 produced  $637.70 \pm 65.69$  mg/L riboflavin after 60 h, representing a 90% increase compared with BSR (Fig. 5C). This result indicate that the expression of the complete *rib* operon in the *rpe* mutant had a more significant effect on the production of riboflavin. To further enhance the precursor supply, the mid-copy-number plasmid pHP13(spe) carrying the intermediate-strength promoter Pvegl was used to express site-directed mutants of G6PD and 6GPD from *C. glutamicum* [26]. The resulting plasmid pHP03 (G6PD) and pHP04 (6GPD) were introduced into BSR01 to generate BSR03 and BSR04, respectively. The riboflavin titers of BSR03 and BSR04 reached  $880.10 \pm 7.93$  and  $977.29 \pm 63.44$  mg/L at 60 h. On the other hand, the introduction of pMX45 into BSRT generated another strain with high riboflavin production, named BSRT01, which produced  $912.68 \pm 12.34$  mg/L riboflavin at 60 h (Fig. 5C) .

## Discussion

In this study, a mutant of ribulose 5-phosphate 3-epimerase (*rpe*) was identified in the genome database of a riboflavin producing *B. subtilis* strain. Then, the wide-type *rpe* was mutated in the genome of a *B. subtilis* strain with a clear genetic background to study the effects of the identified mutation on riboflavin production. The results showed that the production of riboflavin was significantly enhanced in the strain carrying the mutant *rpe*. Additionally, we found that the production of riboflavin was also increased when a nonsense mutation of *rpe* replaced the wide-type one. The production of riboflavin was further enhanced in a strain carrying both the mutant *rpe* and a nonsense mutation of *tkt*. We therefore inferred that the overproduction of riboflavin is associated with the accumulation of the precursor Ru5P.

*B. subtilis* is one of the most commonly used ribose producers, reaching titers of up to 27 g/L in batch fermentation, with a yield of 300 mg ribose g<sup>-1</sup> glucose [32]. However, the yield of riboflavin in batch fermentation is only 60 mg g<sup>-1</sup> glucose [35]. Previous studies of ribose-producing *B. subtilis* strains also showed that many of them carried mutations of *rpe* or *tkt* [29, 30]. Unfortunately, none of these articles

and patents reported the sequence of the mutant genes, and it was unclear if the *rpe* mutation in the database [31] is the same as the one in the ribose producing *B. subtilis*. Nonetheless, the enhancement of riboflavin production by the nonsense mutant of *rpe* indicated that other mutations that deactivate Rpe might also cause the same phenotype.

The purine metabolism of the *rpe* mutant different from the parent strain, especially for the increased accumulation of inosine and guanosine. However, the transcription levels of genes in the purine *de novo* synthesis pathway and OPPP were not changed, except for *zwf* and *ndk*. It indicated that the variations of the purine metabolism do not require much changes of gene expression at the transcriptional level. Additionally, *B. subtilis* is also a producer of nucleosides such as inosine, adenosine, and guanosine, which were generated by the dephosphorylation of nucleotides [36]. However, the accumulation of purine compounds can inhibit enzymes in the purine *de novo* synthesis pathway. Thus these compounds must be secreted out of the cell to alleviate inhibition and maintain normal growth.

In 2018, Wang et al. combined whole-genome and transcriptome sequence analysis to construct the riboflavin overproduction strain *B. subtilis* BS125. This strain produced 4232 mg/L riboflavin after 72 h in shake-flasks fermentation with 100 g/L glucose [3]. The parent of the final strain was BS124, in which none of the genes in the NOPPP was changed and the copy number of *rib* operon was increased through plasmid expression and genomic integration, produced 2525 mg/L of riboflavin. The yield of this strain was 25.25 mg riboflavin g<sup>-1</sup> glucose, which was comparable to the strains constructed in this study (BSR03: 22.00 mg riboflavin g<sup>-1</sup> sucrose, BSR04: 24.43 mg riboflavin g<sup>-1</sup> sucrose, BSRT01: 22.81 mg riboflavin g<sup>-1</sup> sucrose). In our engineered strains, only the plasmid pMX45 carried additional copies of the *rib* operon. Moreover, we only manipulated BSLY in three steps, to obtain each of these strains, which illustrates the importance and effectiveness of engineering the PPP for riboflavin biosynthesis. To construct a more competitive riboflavin producer, more copies of the *rib* operon are needed to ensure a high carbon flux toward the downstream reactions.

## Conclusions

The production of riboflavin in *B. subtilis* can be significantly enhanced by introducing a mutated *rpe* gene at the original chromosomal locus. The combination of the *rpe* mutation and a *tkt* nonsense mutation led to a 15-fold increase of riboflavin production in shake-flask cultivation. The pattern of the purine metabolism in the *rpe* mutant was changed, while the transcription levels of genes related to the PPP and purine *de novo* synthesis pathway remained generally stable. After expressing the *rib* operon and *gnd*, the *rpe* mutant produced 977.29 ± 63.44 g/L riboflavin after 60 h of fermentation. Taken together, these results prove the effectiveness of *rpe* mutation in the construction of genetically modified riboflavin producer.

## Materials And Methods

### Strains, plasmids and reagents



The bacterial strains and plasmids used in this study are listed in Supplementary Table S1. All *B. subtilis* strains were derived from the wild-type *B. subtilis* 168. *Escherichia coli* DH5α was used for routine cloning and plasmid propagation. When required, antibiotics were added to the growth media at the following concentrations: 100 µg/mL spectinomycin for *E. coli* selection, 250 µg/mL for *B. subtilis* selection; 20 µg/mL erythromycin for *B. subtilis* selection; 8 µg/mL chloramphenicol for *B. subtilis* selection; 20 µg/mL neomycin for *B. subtilis* selection. For the Rpe activity assay, NADH was purchased from Beyotime Biotechnology (Shanghai, China), thiamine pyrophosphate was purchased from Sangon Biotech (Shanghai, China), triose phosphate isomerase and R5P were purchased from Aladdin Biochemical Technology Co. (Shanghai, China), glycerophosphate dehydrogenase was purchased from Shanghai Yuanye Biotechnology Co. (Shanghai, China), and Ru5P was purchased from Shanghai ZZBIO Co. (Shanghai, China). The authentic riboflavin standard was purchased from Shanghai Macklin Biochemical Co. (Shanghai, China).

### Construction of strains and plasmids

DNA manipulations were performed using standard protocols. *B. subtilis* transformation was performed according to a published protocol [37]. The deletion of *ykgb*, *yqec*, *yqjl*, *gntZ*, and *zwf* was performed using a published method [38] based on the paraR-neo/cat-araR counter selection system. The site-direct mutation of *rpe* and other mutations were introduced using the same system [38] with minor modifications. (The principle of introducing these mutations were also similar with [39].) The *rpe* and *tkt* nonsense mutants (BSRN, BST, BSRT) were constructed by replacing the start codons (ATG) with stop codons (TAA). A schematic of the strategy to construct the mutants is shown in supplementary Fig.S1. Taking BSRN as an example, the primer pairs *rpe*-ko-UP1/*rpe*-ko-UP2 and *rpe*-ko-DN1/*rpe*-ko-DN2 were used to clone the upstream and downstream sequences flanking the target locus. The primer pair CR1/*rpe*-ko-CR2 was used to clone the cat-araR fragment, while *rpe*-ko-CR2 also carried a direct repeat (DR, 20 bp) sequence, the homologous sequence was also located downstream of the UP fragment. The primers *rpe*-ko-DN1 and *rpe*-ko-CR2 carried the nonsense mutation of *rpe*, which can be introduced into the downstream and cat-araR fragment. (Other mutations can be carried in upstream fragments as well.) With the nucleotides at the upstream and cat-araR end, the upstream, cat-araR, and downstream fragments can be overlapped to generate the UP-CR-DN fragment. This fragment was used to transform BSLY, after which Cm-resistant transformants were selected, and verified by PCR using the primer pair *rpe*-ko-UP1/*rpe*-ko-DN2. The PCR fragment was sequenced to verify the mutations. The verified mutant was incubated in LB broth for 8 h at 37 °C to induce intra-genomic recombination at the two homologous DR fragments, after which the culture was plated onto LB agar plates containing Nm. After incubation at 37 °C for 1 day, Nm-resistant colonies were selected, and verified by PCR using the primer pair *rpe*-ko-UP1/*rpe*-ko-DN2.

The plasmid pMA5(spe) [40], and pHP13(spe) [41] in which the Spe<sup>r</sup> replaced the Cm<sup>r</sup> (chloramphenicol resistance) and Ery<sup>r</sup> (erythromycin resistance), were used for the expression of all genes, except for *tktA*. This gene was cloned into the plasmid pET28A (Novagen, Darmstadt, Germany) for Tkt purification. All of the expression plasmids were constructed using Gibson assembly [42]. Taking pHP01 as an example, the

mutated *rpe* gene was cloned from the genome of BSR (*rpe*<sup>\*</sup>) by PCR using the primer pair *rpe1/rpe2*. And the P<sub>veg1</sub> promoter was cloned from the genome of *B. subtilis* 168 by PCR using the primer pair P<sub>veg1</sub>-1/P<sub>veg1</sub>-2. The vector was amplified by PCR using primer pair pHP13-1/pHP13-2. The gene, promoter, and vector fragments were assembled using the Clon ExpressRmulti kit (Vazyme, Nanjing, China). All primers used in their construction are listed in Supplementary Table S2.

### **Flask fermentation conditions, measurement of cell density, and riboflavin titers**

To test the riboflavin biosynthesis activity of the engineering strains, 20  $\mu$ L of glycerol stock of bacteria were mixed with 100  $\mu$ L of sterile ddH<sub>2</sub>O, spread on an LB agar plate, and incubated at 37 °C for 24 hours. After that, cells were scraped from the plate and suspended in 1 mL of fermentation medium. The resulting cell suspension was used to inoculate fermentation medium to an initial OD<sub>600</sub> of 0.1. The fermentation medium contained 40 g/L sucrose, 15 g/L white corn steep powder (Solarbio, Beijing, China), 1.5 g/L corn steep powder (Solarbio, Beijing, China), 5 g/L NH<sub>4</sub>SO<sub>4</sub>, 5 g/L yeast extract (Solarbio, Beijing, China), 0.5 g/L MgSO<sub>4</sub>, 3 g/L K<sub>2</sub>HPO<sub>4</sub>, 1 g/L KH<sub>2</sub>PO<sub>4</sub>, and appropriate antibiotics. The fermentation was conducted at 37 °C and 180 rpm for 48 h. Samples were taken at 12 h, 18 h, 24 h, 36 h, 42 h, and 48 h to measure the cell growth and riboflavin production. For the strains carrying a nonsense mutation of *tkt* or the pMX45 plasmid, the fermentation time was extended to 60 h. Cell growth was monitored by measuring the optical density (OD) at 600 nm. Determination and calculation of riboflavin concentration was performed as previous paper with some modifications [43]. Culture samples were diluted with 0.1 M NaOH to the linear range of the MAPADA V-1600 spectrophotometer (MAPADA, Shanghai, China). After dissolving for 20 min, 1 mL of the sample was centrifuged at 10,000×g for 2 min to remove the cells, and other insoluble substances. Then the absorbance at 444 nm was immediately measured. The riboflavin concentration was calculated using a standard equation. All the fermentation experiments were performed in triplicates, and the reported results represented the average of three independent experiments.

### **Ribulose 5-phosphate 3-epimerase assays**

The method of determining the ribulose-5-phosphate 3-epimerase activity was described in a previous paper [44]. All enzyme assays were performed at 30 °C. The assay principle is based on the consumption of NADH, coupled with a series of enzyme-catalyzed reactions. Before the reaction, the mixtures were equilibrated for 3 min at the reaction temperature, and the reactions were started by the addition of the cell-free extract. The change in the A<sub>340</sub> due to NADH consumption was measured using a BioTek neo2SM multi-mode reader (BioTek, Vermont, America). The transketolase (TktA from *E.coli*) was purified according to a published method [45]. A BCA protein assay kit (Solarbio, Beijing, China) was used to determine the protein concentration. The enzyme activity assays were performed in triplicates, and the reported results represented the average of three independent experiments.

### **Analysis of gene expression by quantitative qRT-PCR**

Fresh cell culture samples harvested during the exponential growth phase (6 h) in the fermentation medium, were used to extract total RNA using the RNA prep Pure Cell/Bacteria Kit (Tiangen, Beijing, China) following the manufacturer's instructions. The cDNA was synthesized using the FastQuant RT Kit (Novoprotein, Beijing, China) with gDNase and random primers. The qRT-PCR was carried out on a 7500 Fast Platform (Thermo Fisher Scientific, USA) with Real Master Mix (SYBR Green (Novoprotein, Beijing, China)) using 100 ng of cDNA in a total reaction volume of 20  $\mu$ l with 0.25 mmol/L of each primer (See Supplementary Table S2). The fold change of each transcript in each sample relative to the control was measured in triplicate, normalized to the internal control gene (RNA polymerase, *rpoA*) and calculated according to the comparative CT method [46].

### **Purine compounds extraction and HPLC analysis**

Extracellular and intracellular concentrations of purine compounds (adenine, inosine, guanosine, GMP, AMP, IMP, XMP etc.) in the culture suspension were measured using an HP1100 HPLC system (Bio-Rad, USA) equipped with a refractive UV detector. The sampling and measurement was performed according a method described previously [47]. Before sampling, the tube, containing 0.25 mL 1 N KOH, was placed into liquid nitrogen. Then, during flask fermentation, 9.5 mL of samples were taken at 48 hours, and the samples were frozen in liquid nitrogen, stored at -80 °C until analysis. When all of the samples were collected, a further 0.25 mL quantity of KOH was subsequently placed on top of the frozen suspension. The liquid nitrogen-frozen sample was acclimatized to -20°C and then gently thawed at 0-4°C. Then, the samples were centrifuged for 3 min at 20,000  $\times$  g at 0-4°C. The supernatant was neutralized with 88% phosphoric acid and analyzed immediately via HPLC. The mobile phase consisted of solvent A (20mM potassium dihydrogen phosphate, 2.5% acetonitrile, 5 mM tetrabutylammonium hydrogensulfate (TBAHS)) and solvent B (200 mM potassium dihydrogen phosphate, 10% acetonitrile). The analytes were eluted using a linear gradient of 50% solvent A from 0 to 30 min, and 25% solvent A from 30 to 60 min. The measurements were done in three biological replicates which were measured in three technical replicates each, and the reported results represent the average of three independent experiments.

### **Growth assay**

Cells were grown aerobically in LB medium overnight, centrifuged at 5000 $\times$ g for 5 minutes, washed with GMI medium with corresponding carbon source, then adjusted to and OD<sub>600</sub> of 1.0 and spotted onto GMI plates with 8 g/L glucose/ sucrose/ maltose/ fructose as carbon source, respectively. The plates were incubated for 8 h at 37 °C and monitored for growth. The GMI media contained: 2 g/L (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 18.3 g/L K<sub>2</sub>HPO<sub>4</sub>, 6 g/L KH<sub>2</sub>PO<sub>4</sub>, 1.2 g/L sodium citrate, 0.4 g/L Casamino acid, 1 g/L yeast extract, 0.2 g/L MgSO<sub>4</sub>·H<sub>2</sub>O, and 0.05 g/L tryptophan. The growth of the strains was measured in three technical replicates each.

### **Statistical analyses**

All samples were analyzed in triplicate, and the data were presented as the mean  $\pm$  standard deviation for each sample point. Differences were considered statistically significant if P values lower than 0.05 were

obtained.

## Abbreviations

PPP: pentose phosphate pathway; EMP: Embden-Meyerhof-Parnas pathway; OPPP: oxidative pentose phosphate pathway; NOPPP: non-oxidative pentose phosphate pathway; Glu: D-Glucose; G6P: 6-O-Phosphono- $\alpha$ -D-glucopyranose; Ru5P: 5-O-Phosphonato-D-ribulose; X5P: 5-O-Phosphono-D-xylulose; R5P: 5-O-Phosphono-D-ribose; E4P: (2R,3R)-2,3-Dihydroxy-4-oxobutyl dihydrogen phosphate; S7P: (2R,3R,4R,5S)-2,3,4,5,7-Pentahydroxy-6-oxoheptyl dihydrogen phosphate; F6P: 6-O-Phosphono- $\beta$ -D-fructofuranose; PRPP: 1-O-[Hydroxy(phosphonooxy)phosphoryl]-5-O-phosphono- $\alpha$ -D-ribofuranose; IMP: 5'-Inosinic acid; XMP: 5'-2,3-Dihydroxanthylic acid; GMP: 2-Imino-9-(5-O-phosphono- $\beta$ -D-ribofuranosyl)-3,9-dihydro-2H-purin-6-ol; GTP: Guanosine 5'-(tetrahydrogen triphosphate); AMP: 5'-Adenylic acid; DARPP: N-(2,5-Diamino-6-oxo-1,6-dihydro-4-pyrimidinyl)-5-O-phosphono- $\beta$ -D-ribofuranosylamine; ARPP: N-(5-Amino-2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinyl)-5-O-phosphono- $\beta$ -D-ribofuranosylamin; ArPP: 1-[(5-Amino-2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinyl)amino]-1-deoxy-5-O-phosphono-D-ribitol; ArP: 1-[(5-Amino-2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinyl)amino]-1-deoxy-D-ribitol; DHPB: 2-Hydroxy-3-oxobutyl dihydrogen phosphate; DRL: 1-Deoxy-1-(6,7-dimethyl-2,4-dioxo-3,4-dihydro-8(2H)-pteridinyl)-D-ribitol; FBP: 1,6-Di-O-phosphonato-D-fructose; G3P: 2-Hydroxy-3-oxopropyl dihydrogen phosphate; PYR: 2-Oxopropanoate; G6PD: Glucose-6-phosphate dehydrogenase; 6GPD: 6-phosphogluconate dehydrogenase; TBASH: tetrabutylammonium hydrogensulfate; PCR: Polymerase chain reaction; qRT-PCR: real-time quantitative PCR; DR: direct repeat; Nm: neomycin; Cm: chloramphenicol.

## Declarations

### Funding

This work was supported by the National Key R&D Program of China (2018YFA0903700), the Tianjin Science Fund for Distinguished Young Scholars (17JCQJC45300), and Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project (TSBICIP-KJGG-004-03).

### Acknowledgments

Not applicable.

### Author contributions

BY designed and performed the fermentations, HPLC analysis, growth test, qRT-PCR analysis, and other analytical experiments. CL developed the idea for the study. YWS constructed the strains, performed the Rpe assay, analyzed the experimental data, drafted and revised the manuscript. SYF constructed the plasmids under the guide of MMX. All authors read and approved the final manuscript.

### Availability of data and supporting materials

All data generated and analyzed during this study are included in this manuscript and in its Supplemental Table.

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup> School of Biological Engineering, Dalian Polytechnic University, Dalian 116034, China <sup>2</sup> Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China. <sup>3</sup> Key Laboratory of Systems Microbial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China. <sup>4</sup> University of Chinese Academy of Sciences, Beijing 100049, China. <sup>5</sup> College of Biotechnology, Tianjin University of Science & Technology, Tianjin 300457

## References

1. Schwechheimer SK, Park EY, Revuelta JL, Becker J, Wittmann C. Biotechnology of riboflavin. *Appl Microbiol Biotechnol*. 2016;100:2107–19.
2. Pinto JT, Zemleni J: Riboflavin. *Adv Nutr*. 2016;7:973–5.
3. Wang G, Shi T, Chen T, Wang X, Wang Y, Liu D, Guo J, Fu J, Feng L, Wang Z, Zhao X. **Integrated whole-genome and transcriptome sequence analysis reveals the genetic characteristics of a riboflavin-overproducing *Bacillus subtilis***. *Metab Eng*. 2018;48:138–49.
4. Shi S, Chen T, Zhang Z, Chen X, Zhao X. **Transcriptome analysis guided metabolic engineering of *Bacillus subtilis* for riboflavin production**. *Metab Eng*. 2009;11:243–52.
5. Wang J, Wang W, Wang H, Yuan F, Xu Z, Yang K, Li Z, Chen Y, Fan K. **Improvement of stress tolerance and riboflavin production of *Bacillus subtilis* by introduction of heat shock proteins from thermophilic bacillus strains**. *Appl Microbiol Biotechnol*. 2019;103:4455–65.
6. Zhu Y, Chen X, Chen T, Shi S, Zhao X. **Over-expression of glucose dehydrogenase improves cell growth and riboflavin production in *Bacillus subtilis***. *Biotechnol Lett*. 2006;28:1667–72.
7. Liu S, Hu W, Wang Z, Chen T. Production of riboflavin and related cofactors by biotechnological processes. *Microb Cell Fact*. 2020;19:31.

8. Aguiar TQ, Silva R, Domingues L. *Ashbya gossypii* beyond industrial riboflavin production: A historical perspective and emerging biotechnological applications. *Biotechnol Adv.* 2015;33:1774–86.
9. Schwechheimer SK, Becker J, Peyriga L, Portais JC, Wittmann C. **Metabolic flux analysis in *Ashbya gossypii* using (13)C-labeled yeast extract: industrial riboflavin production under complex nutrient conditions.** *Microb Cell Fact.* 2018;17:162.
10. Dmytruk KV, Yatsyshyn VY, Sybirna NO, Fedorovych DV, Sibirny AA. **Metabolic engineering and classic selection of the yeast *Candida famata* (*Candida flarer*) for construction of strains with enhanced riboflavin production.** *Metab Eng.* 2011;13:82–8.
11. Stahmann KP, Revuelta JL, Seulberger H. **Three biotechnical processes using *Ashbya gossypii*, *Candida famata*, or *Bacillus subtilis* compete with chemical riboflavin production.** *Appl Microbiol Biotechnol.* 2000;53:509–16.
12. Heefner DL, Weaver CA, Yarus MJ, Burdzinski LA, Gyure DC, Foster EW: **Riboflavin producing strains of microorganisms, method for selecting, and method of fermentation.** *EP* 1994.
13. Lee KH, Park YH, Han JK, Park JH, Lee KH, Choi H: **Microorganism for producing riboflavin and method for producing riboflavin using the same.** WO; 2006.
14. Bacher A, Eberhardt S, Fischer M, Kis K, Richter G. Biosynthesis of vitamin b2 (riboflavin). *Annu Rev Nutr.* 1999;20:153.
15. Adelbert B, SabineE, Wolfgang E, Markus F, Stefan H, Boris I, Klaus K, Gerald R. **Biosynthesis of riboflavin.** *Vitamins and hormones* 2001, 61:1–49.
16. Schwechheimer SK, Park EY, Revuelta JL, Becker J, Wittmann C. Biotechnology of riboflavin. *Appl Microbiol Biotechnol.* 2016;100:2107–19.
17. Lehninger AL, Nelson DL, Cox MM. Principles of Biochemistry. New York: Worth; 1993.
18. Winkler WC, Cohen-Chalamish S, Breaker RR. An mRNA structure that controls gene expression by binding FMN. *Nat Struct Biol.* 2002;99:15908–13.
19. Maumita M, Benjamin B, Jeffrey EB, Wade CW, Ronald RB. **Riboswitches Control Fundamental Biochemical Pathways in *Bacillus subtilis* and Other Bacteria.** *Cell.* 2003;113:577–86.
20. Saxild HH, Brunstedt K, Nielsen KI, Jarmer H, Nygaard P. **Definition of the *Bacillus subtilis* PurR operator using genetic and bioinformatic tools and expansion of the PurR regulon with *glyA*, *guaC*, *pbuG*, *xpt-pbuX*, *yqhZ-fold*, and *pbuO*.** *J Bacteriol.* 2001;183:6175–83.
21. Arnvig K, HoveJensen B, Switzer RL. **Purification and properties of phosphoribosyl-diphosphate synthetase from *Bacillus subtilis*.** *FEBS J.* 1990;192:195–200.
22. Eriksen TA, Kadziola A, Bentsen AK, Harlow KW, Larsen S. **Structural basis for the function of *Bacillus subtilis* phosphoribosyl-pyrophosphate synthetase.** *Nat Struct Bio.* 2000;7:303–8.
23. Smith JL, Zaluzec EJ, Wery J-P, Niu L, Switzer RL, Zalkin H, Satow Y. Structure.
24. **of the allosteric regulatory enzyme of purine biosynthesis.** *Science* 1994, 264:1427–1433.


25. Ohnishi J, Katahira R, Mitsuhashi S, Kakita S, Ikeda M. **A novel *gnd* mutation leading to increased L-lysine production in *Corynebacterium glutamicum*.** FEMS Microbiol Lett. 2005;242:265–74.
26. Duan YX, Chen T, Chen X, Zhao XM. **Overexpression of glucose-6-phosphate dehydrogenase enhances riboflavin production in *Bacillus subtilis*.** Appl Microbiol Biotechnol. 2010;85:1907–14.
27. Wang Z, Chen T, Ma X, Shen Z, Zhao X. **Enhancement of riboflavin production with *Bacillus subtilis* by expression and site-directed mutagenesis of *zwf* and *gnd* gene from *Corynebacterium glutamicum*.** Bioresour Technol. 2011;102:3934–40.
28. Shi T, Wang YC, Wang ZW, Wang GG, Liu DY, Fu J, Chen T, Zhao XM. **Deregulation of purine pathway in *Bacillus subtilis* and its use in riboflavin biosynthesis.** Microb Cell Fact. 2014;13:1–16.
29. Stincone A, Prigione A, Cramer T, Wamelink MM, Campbell K, Cheung E, Olin-Sandoval V, Gruning NM, Kruger A, Tauqeer Alam M, et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol Rev Camb Philos Soc. 2015;90:927–63.
30. Wulf PD, Vandamme EJ. Production of D-ribose by fermentation. Appl Microbiol Biotechnol. 1997;48:141–8.
31. Ken-ichi S, Masahiko Y. **D-Sedoheptulose-7-phosphate: D-Glyceraldehyde-3-phosphate Glycolaldehydetransferase and D-Ribulose-5-phosphate 3-Epimerase Mutants of a *Bacillus Species*.** Biosci Biotechnol Biochem. 1974;38:1305–10.
32. Elodie B-P, Sigrid CJ, De K, Veronique W, Ceeline G, Waulter P, Adarto C, Patrick P, Nancy HR. **Genome Sequence of EU-Unauthorised Genetically Modified *Bacillus subtilis* Strain 2014–3557 Overproducing Riboflavin, Isolated from a Vitamin B2 80% Feed Additive.** Genome Announc 2015, 3: e00214-15.
33. Wu L, Li Z, Ye Q. **Enhanced D-ribose biosynthesis in batch culture of a transketolase-deficient *Bacillus subtilis* strain by citrate.** J Ind Microbiol Biotechnol. 2009;36:1289–96.
34. Manli W, Howard Z. **Mutations in the *Bacillus subtilis* purine repressor that perturb PRPP effector function in vitro and in vivo.** Curr Microbiol. 2000;41:56–9.
35. Humbelin M, Griesser V, Keller T. **GTP cyclohydrolase II and 3,4- dihydroxy-2-butanone 4-phosphate synthase are rate-limiting enzymes in riboflavin synthesis of an industrial *Bacillus subtilis* strain used for riboflavin production.** J Ind Microbiol Biotechnol. 1999;22:1–7.
36. Chen T, Wu QL, Li XJ, Zhao XM. **The effects of different fedbatch process on vitamin B2 production in *Bacillus subtilis*.** Trans Tianjin Univ. 2006;6:7–12.
37. AKIO Y, YOSHITERU H, MIKIO A, TERUO S, STUDIES OT. Production of nucleoside by microorganisms. J Gen Appl Microbiol. 1965;11:339–53.
38. Anagnostopoulos C, Spizizen J. **Requirements for transformation in *Bacillus subtilis*.** J Bacteriol. 1961;81:741–7.
39. Liu S, Endo K, Ara K, Ozaki K, Ogasawara N. **Introduction of marker-free deletions in *Bacillus subtilis* using the AraR repressor and the ara promoter.** Microbiology. 2008;154:2562–70.
40. Shi T, Wang GL, Wang ZW, Fu J, Chen T, Zhao XM. **Establishment of a markerless mutation delivery system in *Bacillus subtilis* stimulated by a double-strand break in the chromosome.** PloS one.

2013;8:1–10.

41. Dartois V, Coppée JY, Colson C, Baulard A. **Genetic analysis and overexpression of lipolytic activity in *Bacillus subtilis***. Appl Environ Microbiol. 1994;60:1670–3.
42. Peter H, Sierd B, Gerard V. **The effect of restriction on shotgun cloning and plasmid stability in *Bacillus subtilis* Marburg**. Molgenenet. 1987;209:335–42.
43. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, Smith HO. Enzymatic assembly of DNA molecules up to several hundredkilobases. Nat Methods. 2009;6:343–5.
44. Himanshi S, Shraddha P, Bhavik P, Nitin S, Nurudin PJ, Digbijay BK. Development and validation of uv-visible spectrometric method for estimation of water soluble vitamin riboflavin. Int J Pharm Sci Res. 2012;3:3462–6.
45. Dante AM, Juan JC, Richard JSB, Michael PB, Patrick OJO. **Pentose phosphate metabolism in *Leishmania mexicana***. Mol Biochem Parasitol. 2003;130:117–25.
46. Amanatuzzakiah AH, Nicolas S, Frank B. Characterization and multi-step transketolase- $\omega$ -transaminase bioconversions in an immobilized enzyme microreactor (IEMR) with packed tube. J Biotechnol. 2013;168:567–75.
47. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
48. Müller RH, Loffhagen N, Babel W. Rapid extraction of (di)nucleotides from bacterial cells and determination by ion-pair reversed-phase HPLC. J Microbiol Methods. 1996;25:29–35.


## Figures





**Figure 1**


Overview of the riboflavin biosynthesis pathway and related pathways in *B. subtilis*. Glucose enters the oxidative pentose-phosphate pathway (OPPP, orange), and is converted into Ru5P, which enters the purine de novo synthesis pathway (brown), which generates GTP. Ribulose-5-phosphate-3-epimerase catalyzes the interconversion of Ru5P and X5P, enabling the conversion of pentose phosphates back into F6P and G3P via transketolase and transaldolase reactions. EMP (purple) and OPPP are linked via the non-oxidative PPP (NOPPP, blue). As the precursors, GTP and Ru5P enter the riboflavin biosynthesis pathway (yellow) to generate riboflavin. Zwf: glucose 6-phosphate dehydrogenase; YkgB: 6-phosphogluconolactonase; GntZ/YqeC/YqjI: 6-phosphogluconate dehydrogenase; YwlF: ribose-5-phosphate isomerase; Prs: phosphoribosylpyrophosphate synthetase; Rpe: ribulose 5-phosphate 3-epimerase; Tkt: transketolase; YwjH: transaldolase; GuaA: GMP synthetase; RibA: GTP cyclohydrolase II/3,4-dihydroxy-2-butanone 4-phosphate synthase; RibD: 5-amino-6-(5-phosphoribosylamino)uracil reductase; RibE: riboflavin synthase (alpha subunit); RibD: riboflavin synthase (beta subunit).



**Figure 2**


Location and sequence of the *rpe* gene, and riboflavin productivity of *rpe* mutants. (A) Location of *rpe* and other eight genes of the operon on the genome. (B) Nucleotides and amino acids sequence of the wild-type and mutant *rpe*. The numbers on the left indicate the start and stop nucleotide numbers of each line; the numbers on top are the amino acid numbers of the corresponding codons. Sequence of the wild-type *rpe* is shown in black, and adenines from positions 498 to 504 are shown in italics. Sequence of the

mutant rpe gene is shown in green (identical with WT sequence) and red (shifted sequence), while the changed amino acids sequence of Rpe is also shown in red. (C) Comparison of riboflavin production between BSR (rpe504delA), BSRN (rpe0), and their parent strain. (D) Comparison of riboflavin production between BST (tkt0), BSRT (rpe504delA,  $\Delta$ tkt0), and their parent strain.




**Figure 3**

Growth phenotypes of the wild-type and mutant strains grown in GMI media with glucose/sucrose/maltose/fructose as carbon source. (Left) BSLY with wild-type rpe, BSR carrying mutant rpe, BSRN carrying a nonsense mutation of rpe. (Right) BSRNE is a derivative of BSRN harboring the empty vector pHP13(spe), BSRN1 harboring pHP01 carrying the mutant rpe, BSRN2 harboring pHP02 carrying wild-type rpe.



**Figure 4**

Investigation of the mechanism of riboflavin overproduction in the *rpe* mutant. Relative transcriptional levels of genes in the pathways that provide precursors for riboflavin biosynthesis.



**Figure 5**

Metabolic engineering of the initial producer strain harboring the *rpe* mutation to further enhance riboflavin production. (A) Comparison of riboflavin production in strains individually overexpressing the genes involved in the PPP, purine de novo synthesis pathway, and riboflavin biosynthesis pathway. (B) Comparison of riboflavin production in strains carrying deletions of genes involved in OPPP and their parent strain. (C) Comparison of riboflavin production in strains expressing the rib operon.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryMaterials.docx](#)